Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Accounts Payables: 2021-2024

Historic Accounts Payables for Amylyx Pharmaceuticals (AMLX) over the last 4 years, with Dec 2024 value amounting to $2.9 million.

  • Amylyx Pharmaceuticals' Accounts Payables rose 259.05% to $5.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.3 million, marking a year-over-year increase of 259.05%. This contributed to the annual value of $2.9 million for FY2024, which is 86.68% down from last year.
  • Per Amylyx Pharmaceuticals' latest filing, its Accounts Payables stood at $2.9 million for FY2024, which was down 86.68% from $22.1 million recorded in FY2023.
  • Amylyx Pharmaceuticals' 5-year Accounts Payables high stood at $22.1 million for FY2023, and its period low was $2.9 million during FY2024.
  • Moreover, its 3-year median value for Accounts Payables was $6.3 million (2022), whereas its average is $10.4 million.
  • Its Accounts Payables has fluctuated over the past 5 years, first skyrocketed by 252.58% in 2023, then plummeted by 86.68% in 2024.
  • Yearly analysis of 4 years shows Amylyx Pharmaceuticals' Accounts Payables stood at $4.4 million in 2021, then skyrocketed by 43.12% to $6.3 million in 2022, then spiked by 252.58% to $22.1 million in 2023, then plummeted by 86.68% to $2.9 million in 2024.